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Mannose-binding lectin (MBL) targets diverse micro-
organisms for phagocytosis and complement-mediated ly-
sis by binding speciﬁc surface glycans. Although
recombinant human MBL (rhMBL) trials have focused on
reconstitution therapy, safety studies have identiﬁed no
barriers to its use at higher levels. Ebola viruses cause fatal
hemorrhagic fevers for which no treatment exists and that
are feared as potential biothreat agents. We found that mice
whose rhMBL serum concentrations were increased >7-
fold above average human levels survived otherwise fatal
Ebola virus infections and became immune to virus re-
challenge. Because Ebola glycoproteins potentially model
other glycosylated viruses, rhMBL may offer a novel broad-
spectrum antiviral approach.
Circulating mannose-binding lectin (MBL) is a ﬁrst-line host
defense against a wide range of viral and other pathogens. MBL
is a C-type lectin that recognizes hexose sugars including man-
nose, glucose, fucose, and N-acetylglucosamine on the surface of
many pathogens. It does not recognize the terminal carbohy-
drates galactose and sialic acid on normal host cells. Therefore,
MBL preferentially recognizes glycosylated viruses including
inﬂuenza virus, human immunodeﬁciency virus, severe acute
respiratory syndrome coronovirus (SARS-CoV), Ebola virus,
and Marburg virus. It also recognizes many glycosylated gram-
positive and gram-negative bacteria [1, 2]. As a result of com-
mon genetic variants, MBL serum levels in humans range from
0 to 10,000 ng/mL. Thirty percent of the human population has
levels ,500 ng/mL, which are associated with increased sus-
ceptibility to infections in children and immunocompromised
individuals [3].
We previously reported preclinical studies that addressed
the potential utility of recombinant human MBL (rhMBL)
reconstitution therapy. MBL-knockout mice are highly sus-
ceptible to several bacteria including Staphylococcus aureus
[1]. RhMBL improved survival in MBL-null mice to ap-
proximate survival among infected wild-type mice at doses
that reconstituted the complement-activating capacity of
MBL-knockout serum to a level comparable to that of wild-
type mouse serum [1]. Doses of plasma-derived MBL and
rhMBL designed to increase MBL concentrations to physio-
logic levels (.1000 ng/mL) in MBL-deﬁcient humans were
safe in early trials and did not elicit antibodies [3–5]. In
contrast, although MBL replacement therapy enhanced
opsonophagocytic potential, higher levels of plasma-derived
MBL were needed to achieve MBL-mediated complement
activation comparable to healthy controls [6], suggesting that
above-replacement dosing will need attention.
Ebola and Marburg viruses of the ﬁlovirus family are among
the most virulent causes of the human viral hemorrhagic fevers
and cause devastating epidemics of fulminant and rapidly fatal
disease. They constitute important biological threat agents be-
cause of their high mortality rates, capacity for large-scale dis-
semination, and potential for causing social disruption.
Currently, there are no US Food and Drug Administration–
approved therapeutic agents available to prevent or treat these
lethal viral infections. Filovirus surface glycoproteins (GPs) are
heavily glycosylated and contain high-mannose. As a result,
MBL binds to Ebola and Marburg viruses and mediates com-
plement-dependent virus neutralization [2]. Importantly, their
surface glycoprotein structures are characteristic of a broad
group of viruses in which N-linked glycosylation contributes to
viral virulence [7]. Reasoning that MBL treatment is likely to be
safe at supraphysiological levels, we evaluated an in vivo Ebola
virus model to explore the possibility of using MBL as an im-
munotherapeutic agent. Our results showed that supra-
physiological doses of MBL rescued 40% of mice from lethal
challenges when administered pre– or post–Ebola virus exposure.
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evaluated more broadly asan immunotherapeutic agent for a wide
spectrum of glycosylated pathogens.
MATERIALS AND METHODS
Production and pharmacokinetics of rhMBL
Commercial-grade rhMBL was provided by Enzon Pharma-
ceuticals [8]. Human MBL concentrations and complement
cleavage activity were measured as described elsewhere [9].
Pharmacokinetics of rhMBL concentration–time data were
evaluated using noncompartmental modeling with WinNonlin
Professional Edition (version 5.2; Pharsight). The area under the
curve from zero to inﬁnity (AUC0–N) values were calculated
using the linear trapezoidal method.
Murine Ebola model
We used a validated lethal Ebola Zaire mouse model developed
atthe USArmyMedicalResearchInstituteofInfectiousDiseases
(USAMRIID) [10], with a double plaque-puriﬁed, mouse-
adapted, Ebola isolate, EZ’76 Mp3 Vp2 Mp9 GH. The virus was
inoculated intraperitoneally (i.p.) at 100 pfu (3000 3 LD50)
producing uniformly lethal disease in C57B6 mice using bio-
safety level-4 facilities. Research was conducted in compliance
with the Animal Welfare Act and federal regulations in a fully
accredited facility. To assess the effect of rhMBL on virus
lethality, we treated Ebola virus–infected C57B6 mice i.p. with
either 4.3 mg/kg or 20 mg/kg of rhMBL twice daily 12 hours
apart for 10 days. On the day of virus exposure, mice were
treated and exposed to 100 pfu of mouse-adapted Ebola Zaire
either 12 hours before or 1 hour after the ﬁrst dose of rhMBL as
indicated in Figure 1.
Mice were assessed daily for changes in physical ap-
pearance and weight. Viremia was assessed by reverse
transcription-polymerase chain reaction (RT-PCR) and
plaque assays as described elsewhere [11], and anti–Ebola
virus antibodies were measured using standard enzyme-
linked immunosorbent assays (ELISAs) [12]. Standard blood
counts were evaluated with a Coulter A
CT diff (Beckman
Coulter). For analysis with ﬂow cytometry, spleens were
ground into single cell suspensions with the BD Medi-
machine tissue grinder. After incubation with Fc Block (BD),
cells were washed and incubated with antibody (CD3 FITC
BD no. 555274, CD8 V450 BD no. 560469, CD14 PerCP eBio
no. 45-0141, CD4 PE eBio no. 12-0041-82, CD11b APC BD
no. 553312, and CD19 PE-Cy7 BD no. 557655). Cells were
washed with PBS and ﬁxed in BD cytoﬁx. Data were im-
mediately acquired with a BD FACSCantoII and analyzed
with FlowJo (version 7). The Bio-Plex Mouse Cytokine 23-
Plex Panel assay (Bio-Rad 171-F11241) was used to measure
multiple cytokines, chemokines, and growth factors in serum
and tissue supernatants according to the manufacturer’s
instructions. Mice that survived the initial infection were
tested for Ebola-speciﬁc serological response on day 21 and
rechallenged with the same virus dose without further
treatment, and antibody titers were retested 28 days later.
RESULTS
We previously found that rhMBL bound Ebola (Zaire) and
Marburg (Musoke) envelope GPs [2]. RhMBL effectively
blocked Ebola GP interactions with DC-SIGN, and HIV par-
ticles lacking gp120/gp41 pseudotyped with Ebola or Marburg
GPs were neutralized by the lectin complement pathway [2]. To
develop an in vivo test of rhMBL effectiveness, we determined
that 100 ng/mL of rhMBL was the minimum concentration
needed to inhibit >90% infectivity of HepG2 cells using Ebola
GP pseudotyped lentiviral particles and to inhibit >90% in-
fectivity of Vero E6 cells using recombinant Ebola Zaire virus
(Mayinga strain)-eGFP (data not shown). We had previously
found that a single intraperitoneal dose of 75 lg of rhMBL
reconstituted the lectin complement pathway in MBL-knock-
out mice [1]. We compared the pharmacokinetic parameters
(Table 1) of that single reconstitution dose (4.3 mg/kg) with
a higher single intraperitoneal dose of 350 lg (20 mg/kg) to
identify a potentially supraphysiological dose to test in model
infections. The average maximum serum concentration (Cmax)
of both doses exceeded the minimum concentration of MBL
that inhibited infection in vitro by at least 55-fold. The average
ratio of maximum to baseline complement component 4
cleavage activity was 1.7 for the 75-lg rhMBL dose and 5.4 for
the 350-lg dose.
Intraperitoneal administration of 100 pfu of native Ebola
Zaire virus (3000 3 LD50) is uniformly fatal in mice. Treatment
with 75 lg of rhMBL per dose every 12 hours failed to protect
mice from that virus inoculum. Therefore, we increased rhMBL
to 350 lg administered every 12 hours for 10 days starting
either 1 hour before or 12 hours after Ebola virus challenge
(Figure 1A and 1B). When treatment was started 1 hour before
virus infection, the supraphysiological dose increased survival
to . 40% of mice in several trials (Figure 1A). We then started
treatment 12 hours after viral infection. We compared survival in
wild-type and complement component 3 (C3)–deﬁcient mice as
the inhibitory effects of MBL on Ebola virus are mediated by
complement in cell culture [2]. Once again we saw an increase in
survival from 0% to .40% in rhMBL-treated mice, and survival
was dependent on an intact complement pathway, since C3-
deﬁcient mice did not survive (Figure 1B). All inoculated mice
showed signs of infection according to standardized observation
scores and weight loss, and surviving mice had detectable Ebola
virus–speciﬁc antibodies 28 days after infection (data not shown).
We monitored the effect of treatment started 12 hours after
infectiononavarietyoflaboratoryindices.Meanwhitebloodcell
counts were 9100 cells/mL in MBL-treated mice (n 5 5)
176 d JID 2011:203 (15 January) d BRIEF REPORTcompared with 4525 cells/mL on day 7 after infection in the
surviving sham-treated mice (n 5 4). Average lymphocyte
counts were also higher in MBL-treated mice compared with
controls (5500 cells/mL vs 2800 cells/mL, respectively). A similar
trend was seen for platelet counts, which averaged 726,000 cells/
mL in the treatment group and 239,000 cells/mL in the controls.
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Figure 1. Survival and laboratory indices of filovirus-infected mice treated with recombinant human mannose-binding lectin (rhMBL). (A) Mouse
survival when treated with rhMBL before Ebola virus inoculation. Sham-treated wild-type mice were compared with wild-type mice receiving 350 lgo f
rhMBL (referred to as Rx) administered intraperitoneally (i.p.) every 12 hours starting 1 hour before mouse-adapted Ebola virus (EBO) challenge (100 pfu).
Shown is a Kaplan-Meier probability curve for mouse survival at the indicated times (*log-rank Mantel-Cox test, P 5 .0075). (B) Mouse survival when
treated with rhMBL after Ebola virus inoculation. Sham-treated mice were compared with mice receiving 350 lg of rhMBL administered i.p. every
12 hours starting 12 hours after mouse-adapted Ebola virus challenge (100 pfu). Both wild-type (WT) and knockout mice lacking complement component
3 (C3 KO) were compared. Shown is a Kaplan-Meier probability curve for mouse survival at the indicated times (*log-rank analyses; WT: sham-treated vs
rhMBL-treated, P 5 .0013; rhMBL-treated: WT versus C3 KO, P 5 .0003). (C) Platelet count analyses. RhMBL-treated mice had significantly lower
platelet counts on day 5 after Ebola virus inoculation than sham-treated mice (*P 5 .014). (D) Viral plaque assays. RhMBL-treated mice tended to have
lower viral titers than sham-treated mice but the differences were not statistically significant. (E) Intrahepatic cytokine responses. RhMBL-treated
mice had lower proinflammatory and T helper celltype 2 (Th2) cytokine titers in liver homogenates onday 5 after inoculation (P values as shown). (F)Anti–
Ebola virus titers in mice surviving Ebola virus infection. Fifteen wild-type mice received a 10-day course of rhMBL administered every 12 hours that was
started 1 hour before inoculation with 100 pfu of mouse-adapted Ebola virus as indicated. Antibody (Ab) titers were obtained on day 21 and again on day
56. Mice were rechallenged with Ebola virus on day 28. The reciprocals of anti–Ebola virus antibody titers in 5 mice successfully treated with rhMBL are
shown on the indicated days after initial and repeat challenges with Ebola virus.
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on day 5 (672,000 cells/mL vs 322,000 cells/mL, P 5 .014;
Figure 1C).
In a separate experiment, spleens were harvested on day 5
after infection (4 sham-treated and 4 MBL-treated mice).
Constituent cell populations were assayed by ﬂow cytometry.
Numbers of splenic CD3
2CD19
1 cells (B lymphocytes) and
CD11b
1 granulocytes were higher in MBL-treated mice
(89.2% vs 85.1%, P 5 .019; 17.6% vs 12.8%, P 5 .04, re-
spectively). The RNA viral loads as determined by RT-PCR in
b l o o d ,l i v e r ,a n ds p l e e n5d a y sa fter infection were similar in
sham- and rhMBL-treated mice (P . .05). Virus titers in
blood were generally lower on days 1 and 3 in rhMBL-treated
mice as determined by plaque assays (P . .05; Figure 1D). Of
23 cytokines and chemokines tested in serum, liver, and
spleen on day 5 after inoculation, lower values (ﬂuorescence
intensity units) for interleukin (IL)-1b (170 vs 253, P 5 .07),
IL-5 (89 vs 112, P 5 .03), IL-10 (379 vs 518, P 5 .004), IL-13
(264 vs 384, P 5 .008), and IL-17 (120 vs 174, P 5 .028) were
found in liver homogenates from rhMBL-treated mice (Figure
1E). We tested protective immunity in 5 seropositive mice
that survived initial infection by rechallenging them with
native Ebola virus 28 days after initial infection. It is note-
worthy that all MBL-treated survivors also survived the sec-
o n dv i r a lc h a l l e n g e .S i m i l a ro rh i g h e ri m m u n o g l o b u l i nG ,A ,
and M antibody titers were seen 28 days after the second
challenge with the virus (Figure 1F).
DISCUSSION
In the past 3 decades, approved antivirals have increased from
a few nucleoside analogues to well over 40 drugs [13]. The
human immunodeﬁciency virus (HIV) and hepatitis C virus
(HCV) epidemics particularly drove antiviral discovery toward
rationally designed drugs targeting speciﬁc viral enzymes. Al-
though this approach was remarkably effective, the advent of
newly emerging or drug-resistant viruses that threaten humans
calls forthe development of morebroadly activeagents targeting
viral components shared among viruses. N-glycosylation of
viral envelopes is an important such target shared between in-
ﬂuenza, HIV, HCV, West Nile virus, SARS-CoV, Hendra virus,
Nipahvirus, andﬁloviruses(EbolaandMarburg viruses)[7].To
assess one possible strategy against N-glycosylated viruses, we
tested a stringent Ebola virus infection model (3000 3 LD50)i n
mice.
Filovirus infections are characterized by marked lymphope-
nia, severe degeneration of lymphoid tissues, dysregulated
dendritic cell function, and cytokine storms—all hallmarks of
pathogens that subvert both innate and adaptive immune re-
sponses [14]. Nevertheless, survivors exhibit detectable virus-
speciﬁc antibody responses [15]. Therefore, we hypothesized
that administration of a recombinant innate immune molecule
that targets glycosylated viruses might bridge an infected
individual to recovery. Here we show for the ﬁrst time that
rhMBL can be used as a therapeutic agent to achieve serum
concentrations in mice that correspond to levels in humans that
are 7–24-fold higher than average human concentrations and
complement cleaving activity that is .5-fold higher than base-
line values in mice. This result conﬁrms our previous in vitro
data showing that MBL possesses complement-dependent
intrinsic antimicrobial activity [2].
Biological responses of the infected mice to rhMBL treatment
further indicated that our strategy targeted the main pathogenic
effects of Ebola viruses. MBL-treated mice had higher B lym-
phocyte and CD11b
1 granulocyte counts and demonstrated
down-regulation of intrahepatic proinﬂammatory (IL-1b and
IL-17) and Th2 cytokines (IL-5, IL-10, and IL-13) early in the
course of infection (Figure 1E), suggesting that rhMBL may
mitigate the detrimental effects of the characteristic cytokine
storm. MBL-treated mice tended to have greater inhibition
of viral replication on days 1 and 3 after infection (P . .05;
Figure 1D). Most important, rhMBL treatment bridged surviv-
ing mice to development of an effective adaptive immune re-
sponse (Figure 1F). Future experiments will be needed to scale
high-dose rhMBLtherapy for use in larger animal modelsand to
test rhMBL in combination with other promising experimental
therapies such as small molecule inhibitors, coagulation mod-
ulators, antisense technologies, therapeutic antibodies and
Table 1. Pharmacokinetic Parameters of Low- vs High-Dose Recombinant Human Mannose-Binding Lectin (rhMBL) Therapy in
Uninfected Mice
rhMBL
Pharmacokinetic Parameter 75 lg( n5 5) 350 lg( n5 5) P value
Maximum serum concentration (Cmax, lg/ml) 5.9 (1.1) 17.1 (3.8) .024
Half-life (t1/2, hours) 12.6 (1.6) 14.9 (1.9) .4
Area under the curve (AUC0-N, hourslg/ml) 123 (22) 301 (45) .007
Time to maximum serum concentration (Tmax, hours) 2.8 (.9) 2.1 (.7) .6
NOTE. RhMBL was administered by a single intraperitoneal injection. Data are arithmetic mean (6SEM). Statistical differences were analyzed with the Student
t-test (2-tailed). A value of P , .05 was considered to indicate a statistically signiﬁcant difference. rhMBL, recombinant human mannose-binding lectin.
178 d JID 2011:203 (15 January) d BRIEF REPORTcytokines,andpostexposurevaccination.Insummary,wereport
that supraphysiologic rhMBL therapy may be an effective im-
munotherapeutic strategy against Ebola virus, and since Ebola
glycoproteins potentially model other glycosylated viruses,
rhMBL therapy may offer a novel broad-spectrum antiviral
approach.
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